GSL: General Sales Licence
This information is intended for use by health professionals
Covonia Chesty Cough Sugar Free Syrup
For full list of excipients, see section 6.1
Deep red coloured, thick, syrupy liquid.
To loosen stubborn mucus and clear chesty coughs.
For oral use.
Adults, the Elderly and Children 12 years and over: 15ml in dosing cup provided.
The dose should not be repeated more frequently than every 6 hours.
Not more than 3 doses should be taken in any 24 hours. Do not exceed the stated dose.
This product is contraindicated in children under the age of 12 years (see section 4.3).
Do not take with any other cough and cold medicine.
Known hypersensitivity to any of the ingredients - Porphyria.
Not to be used in children under the age of 12 years.
Patients with rare hereditary problems of fructose intolerance should not take this medicine.
Contains Ponceau 4R E124 which may cause allergic reactions.
Keep out of the reach of children.
If symptoms persist consult your doctor.
There are no or limited amount of data from the use of Guaifenesin in pregnant women. As a result, this product is not recommended during pregnancy or in women of childbearing potential not using contraception.
It is unknown whether Guaifenesin/metabolites are excreted in human milk therefore a risk to newborns/infants cannot be excluded. As a result, this product is not recommended during breast-feeding.
Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as:
Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to<1/1000) and very rare (<1/10,000), not known (cannot be estimated from the available data)
Immune system disorders
Unknown: hypersensitivity reactions
Unknown: Abdominal discomfort, nausea and vomiting
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Very large doses of Guaifenesin can cause nausea and vomiting. Vomiting should be treated by fluid replacement and monitoring of electrolytes.
Pharmacotherapeutic Group: Expectorants
ATC code: R05CA03
Mechanism of action/effect
Guaifenesin is a well-known expectorant. Such expectorants are known to increase the volume of secretions in the respiratory tract and therefore to facilitate their removal by ciliary action and coughing.
Absorption and Fate:
Guaifenesin is absorbed from the gastro-intestinal tract. It is metabolised and excreted in the urine.
There are no preclinical data of relevance to the prescriber, which are additional to those already included in other sections of the SmPC.
Sorbitol 70% Solution Non-Crystallising
Ponceau 4R E124
Do not store above 25°C.
Amber glass bottles with polypropylene/polythene caps containing 150ml of product.
Shake well before use.
Thornton & Ross Limited